SCHEMBL6289372

SCHEMBL6289372

Fc1ccc(Cc2cnc3[nH]c(C#CCc4ccccc4)cc3c2)cc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SNCA P37840 1/20 0.35
JAK2 O60674 1/20 0.33
ZAP70 P43403 1/20 0.33
SYK P43405 1/20 0.33
KIT P10721 1/20 0.32
TP53 P04637 1/20 0.32
KDM5A P29375 1/20 0.32
KDM5B Q9UGL1 1/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
KDM1A O60341 1/20 0.32
GRIN1 Q05586 1/20 0.31
GRIN2B Q13224 1/20 0.31
HTT P42858 1/20 0.31
CLPP Q16740 2/20 0.31
MEN1 O00255 1/20 0.30
MAPT P10636 1/20 0.30
PABPC1 P11940 1/20 0.30
KMT2A Q03164 1/20 0.30
MPO P05164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6288962 0.76 S1PR1 (0.36) JAK2ZAP70SYKCYP11B1CYP11B2
SCHEMBL6292723 0.76 CYP11B1 (0.32) JAK2ZAP70SYKCYP11B1CYP11B2
SCHEMBL6288773 0.75 S1PR1 (0.44) JAK2ZAP70SYKTP53CYP11B1
SCHEMBL6289350 0.73 KDM5A (0.45) JAK2ZAP70SYKKDM5AKDM5B
SCHEMBL6292132 0.70 LTA4H (0.31) TP53CYP11B1CYP11B2HTT
SCHEMBL6292129 0.70 MMP13 (0.38) CYP11B1CYP11B2GRIN1GRIN2BMMP13
SCHEMBL6292133 0.68 S1PR1 (0.33) KDM5AKDM5BHTT
SCHEMBL3362040 0.67 CALM1 (0.55) CYP11B1CYP11B2KDM1AHTT
SCHEMBL20004447 0.64 SNCA (0.70) SNCAMAPT
SCHEMBL6292112 0.63 MMP13 (0.41) KDM5AKDM5BMMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949651-B2 Fused bicyclic metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2005-09-27 US disclosed
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors LINCOLN FOODSERVICE PRODUCTS INC. 2004-02-19 US disclosed
WO-2004014375-A2 FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034054-A1 Fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 SNCA 4870/4885JAK2 1307/4885ZAP70 3126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.